Zinc content of commercial diluents widely used in drug admixtures prepared for intravenous infusion

International Journal of Pharmaceutical Compounding

Volumn 11, Issue 5, 2007, Pages 426-432

  Desai, Narendra R ^a   Shah, Syed M ^a   Koczone, Julianna ^a   Vencl Joncic, Maja ^a   Sisto, Christopher ^a   Ludwig, Stephen A ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; DILUENT; DRUG ADDITIVE; METAL ION; PANTOPRAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PLASTICIZER; TRANSITION ELEMENT; ZINC;

CATALYSIS; DEVICE; DRUG DEGRADATION; DRUG INFUSION; DRUG MANUFACTURE; DRUG QUALITY; DRUG STORAGE; DRUG SYNTHESIS; HOSPITAL PHARMACY; PARTICULATE MATTER; PUBLICATION; REVIEW; UNITED STATES;

EID: 34548784959     PISSN: 10924221     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Gallelli JF, Groves MJ. USP perspectives on particle contamination of injectable products. J Parenter Sci Technol 1993; 47(6): 289-292.
2. Committee for Proprietary Medicinal Products (CPMP). The European Agency for the Evaluation of Medicinal Products: Evaluation of Medicines for Human Use. Note for Guidance on Specification Limits for Residues of Metal Catalysts. December 17, 2002. Document CPMP/SWP/QWP/4446/00. [EMEA Website.] Available at: www.emea.europa.eu/pdfs/human/swp/444600en.pdf. Accessed July 27, 2007.
3. Jenke D. Extractable/leachable substances from plastic materials used as pharmaceutical product containers/devices. PDA J Pharm Sci Technol 2002; 56(6): 332.
4. Preston WA, Anderson NR. Glass and rubber closure effects on the pH of water II. A proposed mechanism of interaction. J Parenter Sci Technol 1985; 39(1): 28-47.
5. Hovorka SW, Schöneich C. Oxidative degradation of pharmaceuticals: Theory, mechanisms and inhibition. J Pharm Sci 2001; 90(3): 253.
6. Motola S, Clawans C. Identification and surface removal of incompatible group II metal ions from butyl stoppers. Bull Parenter Drug Assoc 1972; 26(4): 163-171.
7. Bandoh K, Katoh M, Muto Y et al. Metal-induced degradation of β-lactams. Chemotherapy 1991; 39(4): 315-319.
8. Ambados F. Incompatibility between aminophylline and elemental zinc injections. Aust J Hosp Pharm 1996; 26(3): 370-371.
9. Nrapendra N, McNeal E, Obenhuber D et al. Stimuli to the revision process: Particulate contaminants of intravenous medication and the limits set by USP General Chapter 〈788〉. PF 2004; 30: 2272.
10. Tran T, Kupiec TC, Trissel LA. Quality-control analytical methods: Particulate matter in injections: What is it and what are the concerns? IJPC 2006; 10(3): 202-204.
11. Allen LV Jr. Particulates in parenterals. IJPC 2000; 4(1): 43.
12. Boyett JB, Avis KE. Extraction rates of marker compounds from rubber closures for parenteral use. Bull Parenter Drug Assoc 1975; 29(1): 1-17.
13. Trissel LA. Handbook of Injectable Drugs. 8th ed. Washington, DC: American Pharmacists Association; 1994:XIII-XVIII.
14. Van Caillie M, Degenehart H, Luijendijk I et al. Zinc content of intravenous solutions. Lancet 1978; 2(8082): 200-201.